fneur-10-00186.pdf (617.49 kB)
An overview of microRNAs as biomarkers of ALS
Version 2 2023-06-12, 09:00
Version 1 2023-06-09, 16:52
journal contribution
posted on 2023-06-12, 09:00 authored by Greig JoilinGreig Joilin, Nigel LeighNigel Leigh, Sarah NewburySarah Newbury, Majid HafezparastMajid HafezparastAmyotrophic lateral sclerosis (ALS; MND, motor neuron disease) is a debilitating neurodegenerative disease affecting 4.5 per 100,000 people per year around the world. There is currently no cure for this disease, and its causes are relatively unknown. Diagnosis is based on a battery of clinical tests up to a year after symptom onset, with no robust markers of diagnosis or disease progression currently identified. A major thrust of current research is to identify potential non-invasive markers (“biomarkers”) in body fluids such as blood and/or cerebrospinal fluid (CSF) to use for diagnostic or prognostic purposes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), are found at detectable and stable levels in blood and other bodily fluids. Specific ncRNAs can vary in levels between ALS patients and non-ALS controls without the disease. In this review, we will provide an overview of early findings, demonstrate the potential of this new class as biomarkers, and discuss future challenges and opportunities taking this forward to help patients with ALS.
History
Publication status
- Published
File Version
- Published version
Journal
Frontiers in NeurologyISSN
1664-2295Publisher
FrontiersExternal DOI
Issue
186Volume
10Page range
1-9Department affiliated with
- Clinical and Experimental Medicine Publications
Research groups affiliated with
- Neurodegenerative Disease and Ageing Research Centre Publications
- Sussex Neuroscience Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2019-02-18First Open Access (FOA) Date
2019-03-07First Compliant Deposit (FCD) Date
2019-02-14Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC